Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 4,286.00
-19.00 (-0.44%)
Jul 29, 2025, 3:30 PM JST
Takeda Pharmaceutical Company Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
96.55M JPY
Profits / Employee
2.27M JPY
Market Cap
6,694.04B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| Daiichi Sankyo Company | 19,765 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 13,643 |
| Shionogi & | 4,955 |
| Olympus | 29,297 |
| Sysmex | 10,533 |
Takeda Pharmaceutical Company News
- 9 hours ago - Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings - Benzinga
- 8 days ago - Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration - Business Wire
- 12 days ago - Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector - Seeking Alpha
- 15 days ago - Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1 - Business Wire
- 4 weeks ago - Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 - Business Wire
- 4 weeks ago - Takeda Announces New Assignments of Directors - Financial Post
- 4 weeks ago - Takeda Announces New Assignments of Directors - Business Wire
- 2 months ago - European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD - Business Wire